



OVERVIEW OF POTENTIAL ADVERSE EFFECTS OF HUMAN PHARMACEUTICALS IN AFRICA AQUATIC ECOSYSTEM.

**Vanessa Edwige Tchadji Mayoudom^{*1}, Estella Tembe-Fokunang¹, Serg Hubert Zebaze Togouet²,
Omgba Yves Tabi¹, Nene Ahidjo¹, Olivia Fossi Tankoua³, Samuel Ngum⁴ and Charles Ntungwen Fokunang^{1*}**

¹Department of Pharmacotoxicology & Pharmacokinetics, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Cameroon.

²Department of Animal Biology and Physiology, Faculty of Sciences, University of Yaoundé 1, Cameroon.

³Institute of Fisheries and Aquatic Sciences, Yabassi, University of Douala, Cameroon.

⁴Mbingo Baptist Hospital, Northwest Region, Cameroon.

***Corresponding Author: Vanessa Edwige and Charles Ntungwen Fokunang**

Department of Pharmacotoxicology & Pharmacokinetics, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1.

Email ID: charlesfokunang@yahoo.co.uk

Article Received on 16/06/2022

Article Revised on 06/07/2022

Article Accepted on 27/07/2022

ABSTRACT

Drugs are used for the treatment of various medical conditions in humans, wild animals, livestock, and plants, finding their way into rivers, lakes, and drinking water systems. In these environmental conditions, they can have undesirable effects on both aquatic and human health. There has been a steady increase on the availability of information on contamination of water sources caused by pharmaceuticals in some African countries. The objective of this study was to conduct data mining on published works on the occurrence of human pharmaceuticals in Africa. All available data using different search engines, web data, google scholar was assembled to generate useful information. The results revealed that twenty-eight (28) countries have well documented information on pharmaceutical aquatic contamination. There is a gap of information concerning their occurrence in aquatic biota. This study also focused to produce results that gives an overview on the human pharmaceutical in aquatic environment in Africa.

KEYWORDS: human Pharmaceuticals, Africa, water, aquatic biota, ecosystems.

1-INTRODUCTION

Consumption of pharmaceuticals is increasing worldwide to sustain the health of humans and animals. These compounds constitute a large group of over 4000 chemicals that are primarily used for therapeutic purposes in both humans and animals. Pharmaceuticals and their metabolites find their way into the environment through various mechanisms including direct disposal of intact drugs into the environment, excretion of human and animal wastes on the ground, direct release from the manufacturing industries, veterinary and agricultural practices.^[1, 2] In addition, due to their high polarity and solubility, they can move through traditional wastewater treatment plants (WWTPs) and get discharged into the environmental water bodies as effluents.^[3] Pharmaceuticals are one of the most persistent groups of pollutants in the environment which could ultimately pose a serious health risk to humans and aquatic biota. Bioaccumulation studies have shown the presence of these compounds in various tissues of fish including muscles^[4], gills^[5], blood plasma^[6], brain^[5] and liver.^[7] Prolonged exposure of these compounds promotes antibiotic resistance which could hugely affect public health.^[8, 9] Pharmaceuticals are regarded as contaminants of emerging concern (CEC) that exist in lower

concentrations in various surface waters. They exclusively own intrinsic features that could further pose a threat to the community even at trace levels. Few reports have been recently documented about their adverse effects including endocrine disruption, chronic toxicity as well as the development of new strains within microorganisms which could be resistant against antibiotic action.^[10, 11] This calls for a proper monitoring of their occurrence and distribution in various environmental water bodies. The occurrence of pharmaceuticals in river water was first reported in 1970s and since then, the monitoring of pharmaceuticals in the aquatic environment has become of interest in the wastewater treatment researches.^[12] The different routes of environmental pollution by pharmaceuticals have been illustrated in Figure 1.

For a better understanding of the likely effects of these pharmaceutical exposures, it is important to have a knowledge of their concentrations and global distribution in the environment. This is the motivational basis to review on the distribution and occurrence of pharmaceuticals in different water compartments within the targeted African region. The objective of this study was to conduct data mining on published works on the

occurrence of human pharmaceuticals in Africa. All available data, using different search engines, web data, google scholar, was assembled to generate useful

information. This study also focused to produce results that gives an overview on the human pharmaceuticals in aquatic environment in Africa.




Figure 1: Different routes of environmental pollution by pharmaceuticals^[1]

2-MATERIEL AND METHODS

The study target included all the 54 countries of the African Union. The scope of this literature review and data mining was mapped out on the African countries. The countries of interests were selected based on the availability of published data on the presence of pharmaceuticals and/or their transformation by products in the environmental matrices. The environmental matrices considered included wastewater, drinking water, sediments, rivers, lakes, hospital waste, macroinvertebrates, fish. This review includes studies from 2000 to 2022. The search keywords were “active chemicals, transformation by products or metabolites, environmental contaminants, human pharmaceuticals” and each country of Africa. The result was a database that were extracted from studies of all African countries.

3-RESULTS

3.1-Pharmaceuticals in African water bodies and sediments

A twenty years data showed that only 28 out of the 54 African countries have studies on the human pharmaceuticals' occurrence in environmental compartments. It is known that therapeutic consumption of active chemicals to promote human health is usually followed by excretion of these drugs via urine or faecal matter, due to their slight alteration of the human

metabolism. The detection of several active chemical classes including nonsteroidal anti-inflammatories, antibiotics, antiretrovirals, anti-epileptics, steroid hormones, and anti-malarial drugs, has been reported in water resources, influents, and effluents in some countries in Africa.^[13-23] Occurrences of active chemicals in Africa water bodies are reported in Tables 1 to 14.

3.1.1. Kenya

Reports of the presence of active chemicals in the Kenyan environment are available.^[19-21, 23] Some exclusive data on the concentrations and loads of chemicals such as antibiotics, antivirals, analgesics, anti-inflammatories, and psychiatric drugs are presented in Table 1.

3.1.2 Uganda

The presence of quantifiable levels of active chemicals was investigated in Uganda's environmental compartments.^[22-24] The results indicate the presence of active chemicals belonging to multiple therapeutic categories, as presented in Table 2.

3.1.3. Tanzania

In Tanzania, as in other sub-Saharan countries, waste water treatment plants are not designed for the removal of emerging contaminants such as active chemicals.

Wastewater stabilization ponds are utilized to partially treat the effluents from industries, residential areas, and hospitals. Therefore, when effluents are released into the

ecosystem, the chemical load is increased.^[23, 25-28] Occurrences of the active chemicals in the Tanzanian environment are presented in Table 3.

Table 1: Occurrence of Pharmaceuticals in Kenya aquatic ecosystem.

| Substances | Effluents | Surface Water (ng/L) | Sediments (ng/Kg) | References |
|------------------|-----------|----------------------|-------------------|------------|
| Norfloxacin | 4.2 | 1.6-4.9 | 246-776 | [21] |
| Trimethoprim | 15.8 | 3.8-44 | 11-90 | |
| Ciprofloxacin | 5.3 | 2.5-2.8 | 125-1225 | |
| Sulfamethoxazole | 956.4 | 96.9-142.6 | 542-896 | |
| Lamivudine | 847.1 | 219.6-228.3 | 107-491 | |
| Zidovudine | 1.4 | 1.1-21 | 118-510 | |
| Clavulanic acid | 10-110 | | | [29] |
| Erythromycin | 100-150 | | | |
| Sulfamidin | 0-5 | | | |
| Sulfamerazin | 2-20 | | | |
| Tetracyclin | 10-180 | | | |
| Trimethoprim | 5-100 | | | |
| Lincomycin | 5-80 | | | |

Table 2: Occurrence of pharmaceuticals in Uganda aquatic ecosystem.

| Matrix | Substance | Concentration (ng/L) | References |
|---------------------|------------------|----------------------|------------|
| Lake Victoria Water | Sulfamethoxazole | 1-5600 | [22] |
| | Trimethoprim | 1-89 | |
| | Tetracyclin | 3-70 | |
| | Sulfacetamide | 1-13 | |
| | Erythromycin | 10-66 | |
| | Sulfamethazin | 2-50 | |
| | Carbamazepin | 5-72 | |
| | Ibuprofen | 6-780 | |
| | Diclofenac | 2-160 | |

Table 3: Occurrence of pharmaceuticals in Tanzania aquatic ecosystems.

| Matrix | Substance | Concentration (ppm) | References |
|-----------------------|---------------|---------------------|------------|
| Wastewater | Metronidazole | 0.065-0.104 | [26] |
| Msimbasi river waters | Metronidazole | 0.0024 | [28] |
| | Paracetamol | 0.006 | |
| | Cetirizine | 0.073 | |
| | Ibuprofen | 0.0016 | |
| Waste water effluents | Ampicillin | Bld-0.367 | [25] |
| | Ciprofloxacin | Bld-0.037 | |

Bld: below detection limit

3.1.4. Zambia

According to the available information, Zambia's environmental compartments were mostly affected by the presence of active chemicals from the classes of

antibiotics and antivirals, as presented in Table 4. As there were only a few studies available, there is a need to further investigate their presence in the Zambian environment.^[23, 26]

Table 4: Occurrence of pharmaceuticals in Zambia aquatic ecosystem.

| Matrix | Substance | Concentration (ng/L) | References |
|---------------|------------------|----------------------|------------|
| Surface water | Sulfamethoxazole | 7740000 | [30] |
| | Trimethoprim | 12800 | |
| | Lamivudine | 10010 | |
| | Antibiotics | 11.8 | |
| | Antivirals | 49700 | |
| Effluents | Antibiotics | 100-300.4 | [30] |
| | Antivirals | 680-55.76 | |

3.1.5. Zimbabwe

Various toxic effects on Zimbabwe aquatic life have been reported as a result of water contamination by industrial and municipal effluents^[23, 31] (Table 5). Industrial processes and domestic products are of diverse

nature and therefore, urban effluents are often contaminated with various anthropogenic endocrine-disrupting chemicals that may interfere with the reproductive physiology of the aquatic fauna.^[25]

Table 5: Occurrence of pharmaceuticals in Zimbabwean aquatic ecosystem.

| Substances | STPs | Ugunza | Matsheumhlope | Kihami | References |
|----------------------------------|------|--------|---------------|--------|------------|
| 17 β -estradiol equivalent | 33 | 237 | 9 | 2 | [31] |
| Dihydrotestosterone equivalent | 55 | - | - | - | |
| Androgenic | 93 | - | - | - | |

*Concentrations are in ng/L

3.1.6. Mozambique

Reports of occurrence of active chemicals in the Mozambican environmental compartments are available.^[32] The active chemicals identified are

presented in Table 6. Remnants of these substances, their metabolites, and their transformation products have detrimental effects on the ecosystems.

Table 6: Occurrence of pharmaceuticals in Mozambican aquatic ecosystem

| Matrix | Substance | Concentration (ng/L) | References |
|---------------|------------------|----------------------|------------|
| Surface water | Sulfamethoxazole | 12 | [29] |
| | Oxytetracyclin | 1000 | |
| | Trimethoprim | 800 | |
| | Azithromycin | 8 | |
| | Clavulanic acid | 5–20 | |
| | Erythromycin | 20–1000 | |
| | Sulfapyridine | 800–1300 | |

3.1.7. Ethiopia

The recent identification of pharmaceuticals^[23, 33] in the Ethiopian environment is presented in Table 7.

Table 7: Occurrence of pharmaceuticals in Ethiopian aquatic ecosystem

| Matrix | Substance | Concentration (ng/L) | References |
|----------------|---------------|----------------------|------------|
| Hospital water | Albendazole | 210 | [33] |
| | Caffeine | 320 | |
| | Trimethoprim | 780 | |
| Waste water | Trimethoprim | 500 | |
| Water | Ciprofloxacin | 10-300 | |
| | Trimethoprim | 7800 | |
| | Caffeine | 3200 | |
| | Albendazole | 2100 | |

3.1.8. Nigeria

Nigeria, as many others sub-Saharan African countries, releases wastewater from hospitals, agriculture, industrial production, and aquaculture into urban waste stabilization ponds. Most wastewater treatment schemes in Nigeria are not designed for the removal of organic contaminants such as active chemical compounds.^[23, 34-36] Occurrences of emerging organic pollutants (EOPs) have been reported, including active chemicals.^[35, 36] (Table 8). Therefore, urban wastewater is the main source of chemical load.

human and environmental health. The status of environmental occurrences of active chemicals in Ghana is presented in Table 9. Anthropogenic activities contribute to the presence of these substances in the environment. In some areas of Ghana, antibiotics, analgesics, drugs for diabetes, anti-malarial drugs, cardiovascular drugs, and anthelmintic drugs are widely used, and may increase the chemical load in the environment.^[23, 37]

3.1.9. Ghana

Reports on Ghana indicate the presence of active chemicals in the environment that may adversely affect

Table 8: Occurrence of pharmaceuticals in Nigerian aquatic ecosystem.

| Matrix | Substance | Concentration | References |
|---|----------------------|--------------------------|------------|
| River water | Phenazone | < to 0.01 µ/L | [35] |
| | Trimethoprim | < to 0.01 µ/L | |
| | Estrone | < to 0.01 µ/L | |
| | Estriol | < to 0.01 µ/L | |
| | Acetylsalicylic acid | < to 0.02 µ/L | |
| | Carbamazepin | < to 0.02 µ/L | |
| | Diclofenac | < to 0.02 µ/L | |
| | Roxithromycin | < to 0.02 µ/L | |
| | Indomethacin | < to 0.02 µ/L | |
| | Erythromycin | < to 0.06 µ/L | |
| | Clofibrac acid | < to 0.02 µ/L | |
| Borehole | Diclofenac | 0.39 mg/L | [34] |
| | Arhemether | 0.62 mg/L | |
| Treated tape | Diclofenac | 0.17 mg/L | |
| | Artemether | 0.04 mg/L | |
| Well water | Diclofenac | 8.84–1100 µg/L | [34] |
| | Ofloxacin | 0.73, 0.24 and 0.08 ng/L | |
| Hospital wastewater and landfill leachate | Acetamidophenol | Bdl–30.1 ng/L | [38] |
| | Oxybenzone | 1.0–1.1 ng/L | |
| | Triclocarban | 39.3–47.2 ng/L | |

Bdl: below detection limit.

Table 9: Occurrence of pharmaceuticals in Ghana aquatic ecosystem.

| Matrix | Substance | Concentration (ng/L) | References |
|---|------------------|----------------------|------------|
| Hospital wastewater effluent/influent, river water, and in vegetables | Tetracycline | 10–300 | [37] |
| | Trimethoprim | 10–200 | |
| | Clavulanic acid | 5–14 | |
| | Azithromycin | 2–12 | |
| | Erythromycin | 10–110 | |
| | Metronidazole | 247-420 | |
| | Ciprofloxacin | 11.352-15.733 | |
| | Erythromycin | 7944-10.613 | |
| | Trimethoprim | 94-4826 | |
| | Tetracyclin | 58-116 | |
| | Oxyeracyclin | 75-252 | |
| | Chlortetracyclin | 16-24 | |
| | Amoxicillin | 2–6 | |
| | Ampicillin | 107–324 | |
| | Cephalexin | 1052–1557 | |
| Sulfasalazine | 2315–3590 | | |

3.1.10. Cameroon

Reports of contamination of the Cameroonian environmental compartments are available; the risk factors leading to contamination have also been identified, for example, the practices that lead to pollution from anthropogenic activities, such as the disposal of municipal and agricultural waste.^[14, 15, 17, 23]

Occurrences of active chemicals in waters in Cameroon contamination of urban and peri-urban tropical watersheds, are presented in Table 10.

Table 10: Occurrence of pharmaceuticals in Cameroon aquatic ecosystem.

| Matrix | Substances | Concentration (ng/L) | References |
|--------------------------|------------------------|----------------------|----------------|
| Hospital wastewater | Diphenhydramin | 377 | [14, 15] |
| | Paracetamol | 211926 | |
| | Clarithromycin | 88 | |
| | Propranolol | 298 | |
| | Cimetidine | 34000 | |
| | Hydroxy omeprazole | 5000 | |
| | Ibuprofen | 141000 | |
| | Tramadol | 76000 | |
| | o-desmethyl tramadol | 141000 | |
| | Erythromycin anhydrate | 7000 | |
| | Ciprofloxacin | 24000 | |
| | Metformin | 154000 | |
| | Sucralose | 13070 | |
| | Azithromycin | 390 | |
| | Sulfamethoxazole | 162 | |
| | Trimethoprim | 265 | |
| | Caffeine | 5800 | |
| | Carbamazepine | 940 | |
| Atenolol | 427 | | |
| Peri-urban surface water | Carbamazepine | 23.8 | [17, 23] |
| | Ibuprofen | 74.2 | |
| | Codeine | 6.6 | |
| | Diclofenac | 55.6 | |
| | Acetaminophen | 13.6 | |
| | Sulfamethoxazole | 36.8 | |
| | Atenolol | 2 | |
| Urban surface water | Carbamazepin | 102.6 | [17] [14] [23] |
| | Ibuprofen | 119.8 | |
| | Codein | 11 | |
| | Diclofenac | 145.4 | |
| | Acetaminophen | 691.6 | |
| | Sulfamethoxazole | 20.8 | |
| | Atenolol | 5.4 | |
| | Ofloxacin | 9 | |
| Ground water | Carbamazepine | 63.8 | [17] [14] |
| | Ibuprofen | 103.6 | |
| | Diclofenac | 109.4 | |
| | Acetaminophen | 27 | |
| | Sulfamethoxazole | 328.6 | |

3.1.11. Botswana

In Botswana, active chemicals were found as a result of the accumulation of antibiotic resistance determinants in wastewater treatment facilities, and their subsequent release into the water ecosystems downstream.^[38] In the

environmental compartments of Botswana, high frequencies of potentially pathogenic microorganisms were observed. The antibiotics that were identified are presented in Table 11.

Table 11: Occurrence of pharmaceuticals in Botswana aquatic ecosystem

| Matrix | Antibiotics | Percentage | References |
|--|------------------|------------|------------|
| Wastewater influent effluent, and downstream environment | Ampicillin | 54 | [38] |
| | Penicillin | 85 | |
| | Erythromycin | 76 | |
| | Cephalosporin | 69 | |
| | Sulfamethoxazole | 54 | |
| | Trimethoprim | 85 | |

3.1.12- South Africa

South Africa is the country having the highest number of publications on the occurrence of pharmaceuticals in

water, surface water, seawater, wastewater and even in sediments.^[1, 13, 16, 18, 23, 29, 39-46] The main results are summarized in table 12.

Table 12: Occurrence of pharmaceutical in South Africa aquatic ecosystem.

| Matrix | Substance (s) | Concentrations | References |
|---------------|--|--------------------|------------|
| Wastewater | Clarithromycin | 5–30 ng/L | [29] |
| | Erythromycin | 10–100 ng/L | |
| | Sulfadimidine | 0–10 ng/L | |
| | Sulfamethoxazole | 5-1000 ng/L | |
| | Sulfapyridine | 5–110 ng/L | |
| | Chlortetracycline | 90 ng/L | |
| | Oxytetracycline | 100 ng/L | |
| Seawater | Ibuprofen | 160 ng/L | [18, 46] |
| | Naproxen | 160 ng/L | |
| Wastewater | Nevirapine | 2100 ng/L | [40] |
| Wastewater | Efavirenz | 17,400 ng/L | [39] |
| Wastewater | Ibuprofen | 117,000 ng/L | |
| Surface water | Ibuprofen | 84,600 ng/L | |
| Water | Concentrations were efavirenz > nevirapine > carbamazepine > methocarbamol > bromacil > venlafaxine. | 164–593ng/L | [41] |
| Surface water | Antiretrovirals (ARVs) | 26.5–430 ng/ L | [42] |
| Sediments | Diclofenac | 92.08 -171.89 ng/g | [46] |
| | Acetaminophen | 34.28–67.92 ng/g | |
| | Carbamazepine | 33.27–61.20 ng/g | |
| | Phenytoin | 8.89–56.55 ng/g | |
| | Sulfamethoxazole | 18.5 ng/g | |

3.1.13- Others African countries

Only one study was found for countries such as Angola, Benin, Burkina Faso, Republic of Congo Brazzaville, DRC Congo, Ethiopia, Gambia, Ghana, Ivory Coast, Lesotho, Liberia, Mali, Morocco, Rwanda, Sierra Leone, South Sudan, Tunisia.^[23] Table 13 is the summary of that study. All the samples were coming from rivers of these countries.

- Concentrations are in ng/L

** 'Other' = Antifungal, antimalarial, antiviral/-retroviral, benzodiazepine, calcium channel blocker, diuretic, histamine H2 receptor antagonist, opioid, oral contraceptive, selective oestrogen receptor modulator and β 2 adrenergic receptor agonist (anti-asthma).

Table 13: Occurrence of pharmaceuticals in others African countries.^[23]

| Pharmaceuticals | Analgesics | Antibiotics | Anticonvulsants | Antidepressants | Antihyperglycaemics | Antihistamines | β -blockers | Other** |
|-------------------------------|------------|-------------|-----------------|-----------------|---------------------|----------------|-------------------|---------|
| Angola | 11300 | 5580 | 870 | 4,91 | 5440 | 0 | 128 | 1040 |
| Benin | 194 | 8,62 | 0 | 0 | 201 | 0 | 0 | 0 |
| Burkina Faso | 0 | 684 | 8,7 | 0 | 246 | 0 | 27,3 | 146 |
| Republic of Congo Brazzaville | 5480 | 3800 | 19,2 | 0 | 486 | 28,3 | 22 | 381 |
| DRC Congo Bukavu | 21000 | 15600 | 73,3 | 0 | 5760 | 0 | 37,6 | 1200 |
| DRC Congo Kinshasa | 9440 | 4520 | 64,8 | 0 | 1660 | 0 | 0 | 970 |
| Ethiopia | 5290 | 2040 | 640 | 0 | 6970 | 24,3 | 125 | 763 |
| Gambia | 15,3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ghana | 872 | 14800 | 219 | 0 | 2570 | 176 | 69,6 | 473 |
| Ivory Coast | 155 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lesotho | 181 | 728 | 40 | 0 | 1730 | 12,9 | 45,7 | 199 |
| Liberia | 407 | 99 | 2,39 | 0 | 78,4 | 0 | 0 | 33,3 |
| Mali | 425 | 650 | 15,7 | 0 | 583 | 0 | 27,8 | 390 |
| Morocco | 4,76 | 72,8 | 112 | 0 | 744 | 27,1 | 0 | 44,9 |
| Rwanda | 79,9 | 117 | 0 | 0 | 50,4 | 0 | 0 | 22,9 |
| Sierra Leone | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28,1 |
| South Sudan | 354 | 556 | 30,1 | 0 | 129 | 12,9 | 0 | 198 |
| Tunisia | 32700 | 1100 | 1970 | 247 | 16800 | 424 | 460 | 1770 |

3.2-Pharmaceuticals in aquatic biota

Research work in Africa on detection and quantification of human pharmaceuticals in fish and invertebrates are

rare. We found only 3 online publications. One was done on sea invertebrates. Two others concerned fish from a lagoon and fish for human consumption.

Table 14: Occurrence of pharmaceuticals in aquatic biota.

| Aquatic biota | Substances | Concentrations | References |
|---|------------------|-------------------|------------|
| Invertebrates (Sea snail, Limpets, Mussels, Starfish, Sea urchins) | Diclofenac | 67.67–780.26 ng/g | [46] |
| | Carbamazepine | 22.32–81.76 ng/g | |
| | Sulfamethoxazole | 35.85–272.09 ng/g | |
| | Lamivudine | 14.02–47.98 ng/g | |
| | Acetaminophen | 17.53–131.08 ng/g | |
| | Phenytoin | 21.51–131.22 ng/g | |
| Fish in South Africa (Snoek, Bonito, Panga, Hottentot) | Diclofenac | 551.8-1812 ng/g | [47] |
| | Acetaminophen | 17.95-33.26 ng/g | |
| | Phenytoin | 55.67-22.2 ng/g | |
| | Sulfamethoxazole | 36.34-688.6 ng/g | |
| | Carbamazepine | 5.16-22.9 ng/g | |
| | Caffeine | 2.3-64.78 ng/g | |
| Fish in Nigeria (Sole, Tilapia, Grouper, Catfish, Silver catfish, Croaker, Red snapper) | Tramadol | 0.8 ng/g | [48] |
| | Trimethoprim | 0.1-19.2 ng/g | |
| | Fluoxetine | 3.2-27.1 ng/g | |

4-DISCUSSION

Assessment of the environmental risk posed by pharmaceuticals and their metabolites has become a major focus in recent years because of their continuous introduction into aquatic systems. In the African context, the fact that water is classified as a scarce resource, makes the situation even more critical as there are relatively few water resources.^[1] Although pharmaceuticals may be present in aquatic environments in low concentrations, their extensive use, high reactivity with biological systems, continuous release and relatively low degradation makes them pseudo-persistent in aquatic environments. The potential effects to the environment and public health are chronic rather than acutely toxic, and depend on exposure, that is, bioavailability, susceptibility to the compound in question, and the degradability of the compound.^[1] Pharmaceuticals can therefore pose potential environmental and public health issues that are of importance to Africa.

4.1-Environmental impacts

Pharmaceuticals are designed to interfere with specific metabolic, enzymatic, or cell-signalling mechanisms at low concentrations through a specific mode of action in humans. The persistence of pharmaceuticals in the environment and chronic exposure to these chemical stressors can have ecotoxicological effects on non-target organisms.^[6] The nature of the aqueous environment, together with the physicochemical properties of the pharmaceuticals, also play an important role as they determine whether the pharmaceuticals will succumb to the processes (including the employed treatment) or persist in the environment.^[2, 6] For example, fluoroquinolones, sulfonamides, trimethoprim and cephalosporins are resistant to microbial biodegradation and tend to persist in the environment and other

environmental compartments.^[7] Fluoroquinolones also have strong adsorptive properties and tend to accumulate on sediments and other organic matter thus elevating their persistence in environmental matrices. In addition, the presence of antimicrobial compounds in the waste water at particular levels can reduce and/or inhibit the growth of sludge bacteria that are involved in biotransforming drugs and degrading organic matter. This inhibition can decrease the efficiency of the waste water treatment plant and may result in contamination of receiving water bodies.^[3, 5] Toxicity studies of fish, daphnia and algae have been used to predict environmental concentrations and ecological risk of most pharmaceuticals.^[7] The biological activity of pharmaceuticals released in aquatic systems has been observed in nature and laboratory investigations have shown that they cause both acute and chronic effects. For example, the antibiotics clarithromycin, sulfamethoxazole, ofloxacin, lincomycin, enrofloxacin and ciprofloxacin have been reported to be toxic to freshwater algae.^[9] Low concentrations (in nanograms/litre) of the synthetic oestrogen 17- α -ethinyloestradiol often used in contraceptive pills have been shown to enlarge fish livers and affect the sexual characteristics of male fish in surface water.^[8] The anti-inflammatory drug diclofenac also seems to be cause for concern for aquatic organisms.^[8, 11] A study done by Fent *et al*^[12], that diclofenac was associated with the disappearance of the Orient white backed vulture in India and Pakistan. In mammals, diclofenac has been reported to affect the liver and kidneys. Furthermore, propranolol (a beta-blocker) detected in Northeastern Spain was reported to have toxic effects on zooplankton and benthic organisms.^[7]

4.2-Public health impacts

Drinking water and consumption of aquatic organisms are two ways in which humans can be exposed to pharmaceuticals that pollute the aquatic environment. Therefore, possible risks of exposure for human health are a subject of concern, especially for the countries that use surface water as their main source of drinking water. Several quantitative pharmaceutical risk assessment studies on exposure to trace levels of pharmaceuticals in drinking water, conducted in different parts of the world, have shown very low risks to human health based on toxicological data.^[49, 50] However, these studies do not rule out possible effects on human health as some studies are often based on limited sets of monitoring data which do not consider long-term effects of exposure and have limited knowledge on the mixed effects of pharmaceuticals in drinking water consumed by humans.^[8,50] In addition, some studies focus on pharmaceutical concentrations in surface water only, and not drinking water, to assess human health risk, assuming that drinking water treatment plants do not remove any of the pharmaceuticals.^[51, 52]

Another risk is the development of resistance to antimicrobial compounds. The presence of antibiotics in treated waste water is increasing and will lead to higher mortality and morbidity as untreatable infectious diseases increase.^[52] Antimicrobial resistance has become a great challenge in clinical therapy mainly because it compromises the effectiveness of antibiotics, resulting in therapeutic failure, elevated health costs, and increased morbidity and mortality rates.^[53] For example, pathogens such as multidrug resistant *Klebsiella pneumoniae* cannot be treated with any antibiotic currently on the market.^[52] Moreover, the overuse and misuse of antibiotics may cause a risk to human health by promoting antibiotic resistant bacteria and antibiotic resistance genes in aquatic environments.^[2, 5] This occurs as a result of the high selective pressure imposed by antibiotics on bacteria. The bacterial community, that can withstand this antimicrobial pressure, will survive and multiply, leading to more resistant strains in the aquatic environments.^[53] The resistant genes can be horizontally transferred from animal to human pathogens and also across different classes of antibiotics used in veterinary and medical contexts, especially when the antibiotics have the same mechanism of action.^[11] This is a major health concern.

4.3-Research gaps and future perspectives in Africa

The presence, persistence and toxicity of pharmaceuticals in the aquatic environment is an important subject that needs to be extensively investigated to help prevent effects on the environment and human health. There is a lack of baseline studies in Africa to counter any effects that can be caused by the presence of pharmaceuticals in African water systems. Africa has particular challenges, such as a high burden of malaria and infectious diseases. This points to a high use of antimalarial drugs and antibiotics, resulting in

relatively high concentrations being released into aquatic environments. Therefore, there is a need to quantify and determine their fate, and extrapolate their possible long-term effects on the environment and public health. There have been few studies conducted in Africa on pharmaceutical drugs in water and their biodegradation profile.

Currently, water treatment processes in Africa cannot remove pharmaceuticals completely, resulting in their discharge into water bodies. There is a need for research to determine how these sewage treatments are efficient in removing different types of pharmaceuticals. This can also be applied to drinking water plants that use potentially contaminated surface water as their source. This will help redesign treatment plants that can exhaustively remove pharmaceuticals that can be toxic or harmful to the environment and human beings. Most quantitative pharmaceutical risk assessments have focused on urban areas, neglecting the rural populations that mostly use impurified water for drinking. Therefore, studies in rural areas in Africa will provide relevant information on the occurrence and fate of pharmaceuticals in the environment that can be compared to studies in urban areas. These pharmaceuticals affect human and aquatic life. Several studies suggest diverse negative effects on aquatic life that are exposed to these trace amounts of pharmaceuticals in their habitats.

Health-care waste disposal is another way by which environment is polluted. When health-care waste is placed in landfills or buried, contamination of groundwater may occur and may result in the spread of some pathogens. If landfills are insecure, expired drugs may come into contact with children and scavenging animals. Evidence suggests that the presence of antibiotics in waste water may be contributing to antibiotic resistance, and if these antibiotics are present in waste water for a longer period, they may cause genetic effects in humans and aquatic life. It is therefore essential that health-care facilities dispose of all waste in accordance with national, provincial, regional and municipal regulations and legislation. Hence, it is essential to raise public awareness and encourage consumers to adopt proper disposal practices for unwanted pharmaceuticals.

CONCLUSION

This work reviewed studies available on the distribution and occurrence of human pharmaceutical in Africa environmental compartments. We found reports on 28 over 54 African countries. Most of the studies were done on the water bodies: drinking water, lake, rivers, waste water and sediments. Studies on pharmaceuticals occurrence in aquatic organisms were scarce and were only found in Nigeria and South Africa. The results intended to reveal, in Africa, the countries with well documented information on pharmaceutical aquatic contamination as well as there is a gap of information

concerning their environmental and public health impact. More studies need to be conducted on aquatic ecosystems in Africa in order to understand and confirm aquatic biota and human health risk. Furthermore, there should funded research and development to optimise water treatment technologies and to improve national, provincial, regional and municipal regulations and legislation.

Authors' contributions This work was carried out in collaboration among all authors. Authors FCN, VETM, ETF, SHZT designed the study; Authors OYT, NA, OFT, SN did data mining and organization; authors FCN, VETM sorted information and contributed in writing of the first draft. All authors read and approved the final draft.

ACKNOWLEDGEMENTS

This project was done in collaboration with the research team of the laboratory for preclinical animal and Pharmacotoxicology research group of the Faculty of Medicine and Biomedical Sciences, of the University of Yaoundé 1, Cameroon. We acknowledge financial support from the research mobilization funds from the Ministry of Higher Education (MINESUP), of Cameroon.

Conflicts of interest: The authors declare that there is no conflict of interest.

REFERENCES

- Ngqwala. N.P., M., P, *Occurrence of pharmaceuticals in aquatic environments: A review and potential impacts in South Africa*. S. Afr. J. Sci, 2020; 116: p. 1-7.
- Pothitou, P., Voutsas, D. , *Endocrine disrupting compounds in municipal and industrial wastewater treatment plants in Northern Greece*. Chemosphere, 2008; 73(11).
- Berendonk TU, M.C., Merlin C, Fatta-Kassinos D, Cytryn E, Walsh F, et al. , *Tackling antibiotic resistance: The environmental framework*. Nat Rev Microbiol, 2015; 13(5): p. 310-317.
- Saravanan M, H.J., Arul N, Ramesh M. , *Toxicological effects of clofibric acid and diclofenac on plasma thyroid hormones of an Indian major carp, Cirrhinus mrigala during short and long-term exposures*. Environ Toxicol Pharmacol, 2014; 38(3): p. 948-958.
- Peltzer PM, L.R., Attademo AM, Junges CM, Teglia CM, Martinuzzi C, et al., *Ecotoxicity of veterinary enrofloxacin and ciprofloxacin antibiotics on anuran amphibian larvae*. Environ Toxicol Pharmacol, 2017; 51: p. 114-123.
- Houeto P, C.A., Guerbet M, Mauclair A, Gatignol C, Lechat P, et al. , *Assessment of the health risks related to the presence of drug residues in water for human consumption: Application to carbamazepine*. Regul Toxicol Pharmacol, 2012. 62(1): p. 41-48.
- Moreno-González R, R.-M.S., Gros M, Barceló D, León V., *Seasonal distribution of pharmaceuticals in marine water and sediment from a Mediterranean coastal lagoon (SE Spain)*. Environ Res, 2015; 138: p. 326-344.
- González Alonso S, C.M., Maroto R, Gil J, De Miguel Á, Valcárcel Y., *Pollution by psychoactive pharmaceuticals in the Rivers of Madrid metropolitan area (Spain)*. Environ Int, 2010; 36(2).
- He K, S.A., Adejumo H, McDiarmid M, Squibb K, Blaney L. , *Detection of a wide variety of human and veterinary fluoroquinolone antibiotics in municipal wastewater and wastewater-impacted surface water*. J Pharmaceut Biomed, 2015; 106 p. 136-143.
- Rehman M, R.N., Ashfaq M, Saif A, Ahmad N, Han J. , *Global risk of pharmaceutical contamination from highly populated developing countries*. Chemosphere, 2015; 138: p. 1045-1055.
- Davies J, D.D., *Origins and evolution of antibiotic resistance*. Microbiol Mol Biol Rev, 2010; 74(3): p. 417-433.
- Fent K, W.A., Caminada D. , *Erratum to "Ecotoxicology of human pharmaceuticals"*. Aquat Toxicol, 2006. 78(2).
- Madikizela, L.M., Ncube, S., Chimuka, L *Analysis, occurrence and removal of pharmaceuticals in African water resources: A current status*. Environ. Manag, 2020; 253(109741): p. 11.
- Longso., P.O.A.N., *Identification et quantification des résidus médicamenteux dans les effluents et les eaux environnant l'Hôpital de référence et la décharge d'ordures ménagères de Douala* . in *Pharmacie*. 2017, Douala: Douala p. 150.
- Tchadji. E. V. M., N.E., Mballa. N. R., Fossi. T. O., Fokunang. C., Chimezie. A., Ngu B. K, *Identification and quantification of 19 pharmaceutical active compounds and metabolites in hospital wastewater in Cameroon using LC/QQQ and LC/Q-TOF*. Environ Monit Assess (2018) 190.: 2018. 190(2018): p. 723-732.
- Ncube S., N.Y., Chimuka L., Madikizela L. M. and Etale A. , *Trace Detection and Quantitation of Antibiotics in a South African Stream Receiving Wastewater Effluents and Municipal Dumpsite Leachates*. Front. Environ. Sci, 2021; 9(733065): p. 9.
- P. Branchet, N.A.C., H. Fenet., E. Gomez ., F. Courant., D. Sebag., J. Gardon., Jourdan., Ngounou Ngatcha., I. Kengne., E. Cadot., C. Gonzalez, *Anthropic impacts on Sub-Saharan urban water resources through their pharmaceutical contamination (Yaoundé, Center Region, Cameroon)*. Science of the Total Environment, 2019; 660: p. 13.
- Ngubane, N.P., Naicker, D., Ncube S., Chimuka L., Madikizela L. M, *Determination of naproxen, diclofenac and ibuprofen in Umgeni estuary and seawater: A case of northern Durban in KwaZulu-*

- Natal Province of South Africa. Reg. Stud. Mar. Sci.*, 2019; 29(100675).
19. Muriuki, C.W., Home, P.G., Raude, J.M., Ngumba, E.K., Munala, G.K., Kairigo, P.K., Gachanja, A.N., Tuhkanen, T.A., *Occurrence, distribution, and risk assessment of pharmaceuticals in wastewater and open surface drains of peri-urban areas: Case study of Juja town, Kenya.* *Environ. Pollut.*, 2020; 267(115503).
 20. K'oreje, K.O., Kandie, F.J., Vergeynst, L., Abira, M.A., Van Langenhove, H., Okoth, M., Demeestere, K., *Occurrence, fate and removal of pharmaceuticals, personal care products and pesticides in wastewater stabilization ponds and receiving rivers in the Nzoia Basin, Kenya.* *Sci. Total Environ.*, 2018; 637: p. 336-348.
 21. Kairigo, P., Ngumba, E., Sundberg, L.-R., Gachanja, A., Tuhkanen, T., *Contamination of Surface Water and River Sediments by Antibiotic and Antiretroviral Drug Cocktails in Low and Middle-Income Countries: Occurrence, Risk and Mitigation Strategies.* *Water*, 2020; 12(1376).
 22. Nantaba, F.W., J.; Kylin, H.; Palm, W.-U.; Bouwman, H.; Kümmerer, K., *Occurrence, distribution, and ecotoxicological risk assessment of selected pharmaceutical compounds in water from Lake Victoria, Uganda.* *Chemosphere*, 2020; 239 (124642).
 23. John L. Wilkinson., A.B.A.B., Dana W. Kolpinb., Kenneth M. Y. Leung., Racliffe W. S. Laic., Cristobal Galban-Malagon., Aiko D. Adelle., Julie Mondonf., Marc Metiang., Robert A. Marchanta., Alejandra Bouzas-Monroya., Aida Cuni-Sancheza., Anja Coorsh., Pedro Carriquiribordei., Macarena Rojoi., Chris Gordonj., Magdalena Carak., Monique MoermondI., Thais Luartem, Vahagn Petrosyann., Yekaterina Perikhanyann , Clare S. Mahono., Christopher J. McGurko., Thilo Hofmannp , Tapos Kormokerq., Volga Iniguezr., Jessica Guzman-Otazos., Jean L. Tavarest., Francisco Gildasio De Figueiredot., Maria T. P. Razzolini., Victorien Dougnon., Gildas Gbaguidi., Oumar Traore., Jules M. Blaisy., Linda E. Kimpey., Michelle Wongz., Donald Wongz., Romaric Ntchantcho., Jaime Pizarrobb., Guang-Guo Ying., Chang-Er Chen., Martha Paez., Jina Martinez-Lara., Jean-Paul Otamonga., John Pote., Suspense A. Ifo., Penelope Wilson, Ilvia Echeverria-Saenz., Nikolina Udikovic-Kolic., Milena Milakovic., Despo Fatta-Kassinoss., Lida Ioannou-Ttofa., Vladimira Belusova., Jan Vymaza., Maria Cardenas-Bustamante., Bayable A. Kassa., Jeanne Garric., Arnaud Chaumot., Peter Gibba., Ilia Kunchulia., Sven Seidensticker., Gerasimos Lyberatosrr., Halldor P. Halldorsson., Molly Mellinga., Thatikonda Shashidhar., Manisha Lamba., Anindrya Nastiti., Adee Supriatin., Nima Pourang., Ali Abedini., Omar Abdullaha., Salem S. Gharbia., Francesco Pilla., Benny Chefet., Tom Topaz., Koffi Marcellin Yao., Bakhyt Aubakirova., Raikhan Beisenova., Lydia Olaka., Jemimah K. Mulu., Peter Chatanga., Victor Ntulieeee, Nathaniel T. Blama., Sheck Sherif., Ahmad Zaharin Aris., Ley Juen Looi, Mahamoudane Niang., Seydou T. Traore., Rik Oldenkamp., Olatayo Ogunbanwo., Muhammad Ashfaq., Muhammad Iqbal., Ziad Abdeen., Aaron O'Dea., Jorge Manuel Morales-Saldana., Maria Custodio., Heidi de la Cruz., Ian Navarrete., Fabio Carvalho, Alhaji Brima Gogra., Bashiru M. Koroma., Vesna Cerkenik-Flajs., Mitja Gombac., Melusi Thwala., Kyungho Choi., Habyeong Kang., John L. Celestino Ladu., Andreu Rico., Priyane Amerasinghe., Anna Sobek., Gisela Horlitz., Armin K. Zenker., Alex C. King., Jheng-Jie Jiang, Rebecca Kariukia., Madaka Tumbo., Ulas Tezel., Turgut T. Onay., Julius B. Lejju., Yuliya Vystavna., Yuriy Vergeles., Horacio Heinzen., Andres Perez-Parada., Douglas B. Sims., Maritza Figyz., David Good., and Charles Teta, *Pharmaceutical pollution of the world's rivers.* *PNAS Environmental Sciences*, 2022; 119(8).
 24. Ekane, N., Mertz, C.K., Slovic, P., Kjellén, M., Westlund, H., *Risk and benefit judgment of excreta as fertilizer in agriculture: An exploratory investigation in Rwanda and Uganda.* *Hum. Ecol. Risk Assess.*, 2015; p. 639-666.
 25. Kihampa, C., *β -lactams and Fluoroquinolone Antibiotics in influents and effluents of Wastewater treatment plants, Dar es Salaam, Tanzania.* *Res. J. Chem. Sci.*, 2014; 2231(606).
 26. Makokola, S.K., Ripanda, A., Miraji, H., *Quantitative Investigation of Potential Contaminants of Emerging Concern in Dodoma City: A Focus at Swaswa Wastewater Stabilization Ponds.* *Egypt. J. Chem.*, 2019; 63: p. 427-436.
 27. Baniga, Z., Hounmanou, Y.M.G., Kudirkiene, E., Kusiluka, L.J.M., Mdegela, R.H., Dalsgaard, A., *Genome-Based Analysis of Extended-Spectrum β -Lactamase-Producing Escherichia coli in the Aquatic Environment and Nile Perch (Lates niloticus) of Lake Victoria, Tanzania.* *Front. Microbiol.*, 2020; 11(108).
 28. Hossein, M., Chande, O., Faustin, N., Erwin, M., *2018. Chem. Sci. Int. J. Spatial Occurrence and Fate Assessment of Potential Emerging Contaminants in the Flowing Surface Waters*, 24: p. 1-11.
 29. Segura, P.A., Takada, H., Correa, J.A., El Saadi, K., Koike, T., Onwona-Agyeman, S., Ofosu-Anim, J., Sabif, E.B., Wasongag, O.V., Mghalu, J.M., et al., *Global occurrence of anti-infectives in contaminated surface waters: Impact of income inequality between countries.* *Environ. Int.*, 2015; 80: p. 89-97.
 30. Ngumba E., G., A., Nyirenda, J., Maldonado, J., Tuhkanen, T *Occurrence of antibiotics and antiretroviral drugs in source-separated urine, groundwater, surface water and wastewater in the peri-urban area of Chunga in Lusaka, Zambia.* *Water SA*, 2020. 46: p. 278-284.

31. Teta, C., Holbech, B.F., Norrgren, L., Naik, Y.S., *Occurrence of oestrogenic pollutants and widespread feminisation of male tilapia in peri-urban dams in Bulawayo, Zimbabwe.* Afr. J. Aquat. Sci, 2018; 43: p. 17-26
32. Remili A., G., P., Pinzone, M., Castro, C., Jauniaux, T., Garigliany, M.-M., Malarvannan, G., Covaci, A., Das, K., *Humpback whales (Megaptera novaeangliae) breeding off Mozambique and Ecuador show geographic variation of persistent organic pollutants and isotopic niches.* Environ. Pollut, 2020; 267(115575).
33. Tegegne B., C.B.S., Zewge F., Chimuka L., *Solid-phase optimisation for simultaneous determination of thirteen pharmaceuticals in Ethiopian water samples with HPLC-DAD detection: An initial assessment.* Environ. Monit. Assess, 2021; 193(310).
34. Ogah C., A., I., Basheeru K., *Pharmaceuticals in the Environment: Levels of Selected Drugs in Water in Lagos, Nigeria.* Niger. J. Pharm. Appl. Sci. Res, 2020; 9: p. 13-18.
35. Oluwatosin O., A., B., Obih, U., Arne, H., Olarinmoye, O., Bakare, A., Ugwumba, O., Hein, A., *Quantification of pharmaceutical residues in wastewater impacted surface waters and sewage sludge from Lagos, Nigeria.* J. Environ. Chem. Ecotoxicol, 2016; 8: p. 14-24.
36. Ogunbanwo, O.M., Kay, P., Boxall, A.B., Wilkinson, J., Sinclair, C.J., Shabi, R.A., Fasasi, A.E.; Lewis, G.A., Amoda, O.A., Brown, L.E., *High Concentrations of Pharmaceuticals in a Nigerian River Catchment.* Environ. Toxicol. Chem, 2020; p. 1-8.
37. Azanu, D., Styrishave, B., Darko, G., Weisser, J.J., Abaidoo, R.C, *Occurrence and risk assessment of antibiotics in water and lettuce in Ghana.* Sci. Total Environ, 2018; 622-623: p. 293-305.
38. Tapela K., R.T., *Isolation and antibiotic resistance profiles of bacteria from influent, effluent and downstream: A study in Botswana.* Afr. J. Microbiol. Res, 2019; 13: p. 279-289.
39. Matongo S., B.G., Moodley B., Ndungu P *Pharmaceutical residues in water and sediment of Msunduzi River, kwazulunatal, South Africa.* Chemosphere, 2015; 134: p. 133-140.
40. Schoeman C., M.M., Dlamini M., Okonkwo O., *Quantification of selected antiretroviral drugs in a wastewater treatment works in South Africa using GC-TOFMS.* J. Chromatogr. Sep. Tech, 2015; 6: p. 1-7.
41. Rimayi C., C., L., Gravell A., Fones G.R., Mills G.A, *Use of the Chemcatcher® passive sampler and time-of-flight mass spectrometry to screen for emerging pollutants in rivers in Gauteng Province of South Africa.* Environ. Monit. Assess, 2019; 388.
42. Wood T.P., D.C.S., Rohwer E, *The occurrence of anti-retroviral compounds used for HIV treatment in South African surface water.* J. Environ. Pollut, 2015; 199: p. 235-243.
43. Madikizela. L.M., T., N.T., Chimuka, L, *Status of pharmaceuticals in African water bodies: Occurrence, removal and analytical methods.* Environ. Manag, 2017; 193: p. 211-230.
44. T.T. Mosekiemanga., M.A.S., A. de Villiers, *Ultra-high pressure liquid chromatography coupled to travelling wave ion mobility-time of flight mass spectrometry for the screening of pharmaceutical metabolites in wastewater samples: Application to antiretrovirals.* Journal of Chromatography A, 2021; 1660(462650): p. 13.
45. Ripanda. A.S., R., M.J., Nyanza. E.C., Njau, K., Vuai, S.A.H., Machunda. R.L, *A Review on Contaminants of Emerging Concern in the Environment: A Focus on Active Chemicals in Sub-Saharan Africa.* Appl. Sci, 2022; 12(56).
46. C. Y. Ojemaye., L.P., *Pharmaceuticals and Personal Care Products in the Marine Environment Around False Bay, Cape Town, South Africa: Occurrence and Risk Assessment Study.* Environmental toxicology and chemistry, 2021; 0(0): p. 21.
47. C. Y. Ojemaye, L.P., *Occurrences, levels and risk assessment studies of emerging pollutants (pharmaceuticals, perfluoroalkyl and endocrine disrupting compounds) in fish samples from Kalk Bay harbour, South Africa.* Environmental Pollution, 2019; 252: p. 562-572.
48. I. Fabunmi., N.S., K. Proctor., A. Oyeyiola., T. Oluseyi, K. Olayinkab., B. Kasprzyk-Hordern, *Multi-residue determination of micropollutants in Nigerian fish from Lagos lagoon using ultrasound assisted extraction, solid phase extraction and ultra-high-performance liquid chromatography tandem mass spectrometry.* Analytical Methods, 2020; 12: p. 2114-2122.
49. De Jesus Gaffney V, A.C., Rodrigues A, Ferreira E, Benoliel M, Cardoso V *Occurrence of pharmaceuticals in a water supply system and related human health risk assessment.* Water Res, 2015; 72: p. 199-208.
50. Houtman C, K.J., Lekkerkerker-Teunissen K, Van der Hoek J, *Human health risk assessment of the mixture of pharmaceuticals in Dutch drinking water and its sources based on frequent monitoring data.* Sci Total Environ, 2014; 496: p. 54-62.
51. Cunningham V, P.C., D'Aco V, Hartmann A, Bechter R *Human health risk assessment of carbamazepine in surface waters of North America and Europe.* Regul Toxicol Pharmacol, 2010; 56(3): p. 343-351.
52. Jain H, M.S., Mullany P *Persistence of endodontic infection and Enterococcus faecalis: Role of horizontal gene transfer.* Gene Rep, 2016. 5.
53. Munier A, D.L.V., Barbier F, Chau F, Fantin B, Ruimy R, *Comparative dynamics of the emergence of fluoroquinolone resistance in staphylococci from the nasal microbiota of patients treated with fluoroquinolones according to their environment.* Int J Antimicrob Agents, 2015; 46(6): p. 653-659.